EIF2AK4 and neuropathy: However, in the case of Gars/CMT2D mouse models, genetically deleting or pharmacologically inhibiting GCN2 not only eliminates ISR activation, but also greatly mitigates the severity of the neuropathy phenotype (Spaulding et al., 2021).